Published in Life Sci on January 01, 1991
Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging (2005) 2.26
Phage display in molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.34
Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol (2011) 1.33
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A (1998) 1.06
Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2006) 0.99
Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging (2007) 0.99
Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging (2003) 0.98
Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging (2012) 0.94
Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer (1998) 0.92
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging (2007) 0.90
Somatostatin receptors on neuroendocrine tumors--a way to intraoperative diagnosis and localization. Yale J Biol Med (1996) 0.89
In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas. J Labelled Comp Radiopharm (2009) 0.86
111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging (2005) 0.85
Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Br J Cancer (1996) 0.84
The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg (1996) 0.84
Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med (2014) 0.82
Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging. Invest New Drugs (2013) 0.78
In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging. Am J Nucl Med Mol Imaging (2014) 0.77
In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. Virchows Arch (2017) 0.75
Somatostatin receptor scintigraphy in patients with pituitary adenoma. Neurosurg Rev (1997) 0.75
SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci (1982) 3.82
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med (2001) 3.69
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med (1993) 3.45
Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med (1990) 2.85
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2005) 2.49
The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev (1991) 2.20
Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med (1989) 2.13
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med (2001) 2.11
[Twenty-five years of cyclosporin use in transplantation medicine]. Ned Tijdschr Geneeskd (2003) 1.94
Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med (1990) 1.93
Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med (1994) 1.93
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res (1999) 1.92
In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging (2006) 1.81
Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77
Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet (1989) 1.76
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging (2007) 1.72
Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab (1990) 1.71
Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child (2002) 1.70
Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev (2001) 1.69
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging (2003) 1.66
Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet (1994) 1.65
Somatostatin-receptor scintigraphy in primary breast cancer. Lancet (1994) 1.63
Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology (1991) 1.57
Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab (1997) 1.57
Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology (1995) 1.54
Peptide receptor imaging and therapy. J Nucl Med (2000) 1.54
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med (1992) 1.54
[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer (2001) 1.53
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem (2002) 1.53
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53
Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology (1993) 1.52
Periplasmic accumulation of truncated forms of outer-membrane PhoE protein of Escherichia coli K-12. J Mol Biol (1986) 1.51
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
Site-directed mutagenesis of the Escherichia coli chromosome near oriC: identification and characterization of asnC, a regulatory element in E. coli asparagine metabolism. Nucleic Acids Res (1985) 1.45
Intracavitary brachytherapy of cystic craniopharyngiomas. J Neurosurg (1992) 1.43
Long-acting somatostatin analog controls acid and gastrin secretion in benign, not in malignant, Zollinger-Ellison syndrome. J Clin Gastroenterol (1989) 1.41
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med (1991) 1.41
Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging (2015) 1.41
Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. J Am Coll Cardiol (1996) 1.40
[Behcet's disease]. Ned Tijdschr Geneeskd (1999) 1.39
Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver. J Nucl Med (1993) 1.38
[Insulinoma and octreotide]. Ned Tijdschr Geneeskd (1992) 1.38
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab (1997) 1.38
Atrophic rhinitis in swine: correlation of Pasteurella multocida pathogenicity with membrane protein and lipopolysaccharide patterns. Infect Immun (1984) 1.34
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res (1989) 1.32
Place of radioactive iodine in treatment of thyrotoxicosis. Lancet (1986) 1.30
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol (2012) 1.30
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med (2001) 1.30
Aorto-caval fistula--an uncommon complication of infrarenal aortic aneurysms. Thorac Cardiovasc Surg (1994) 1.29
Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer (1995) 1.28
Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab (1997) 1.26
Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res (1992) 1.25
Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2012) 1.25
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med (2001) 1.25
Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clin Pharmacol Ther (1988) 1.24
Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med (1993) 1.24
Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl (1986) 1.24
Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut (1996) 1.22
[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci (1991) 1.20
The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) (1993) 1.20
Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med (1993) 1.20